NC
BDTX icon

nVerses Capital’s Black Diamond Therapeutics BDTX Stock Holding History

nVerses Capital’s Portfolio BDTX Stock Details BDTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-31,411
Closed -$66.9K – 314
2026
Q1 		$66.9K Buy
31,411
+20,689
+193% +$49.2K 0.06% 334
2025
Q4 		$26.1K Buy
+10,722
New +$38K 0.06% 194
2024
Q4 		– Sell
-4,300
Closed -$18.7K – 104
2024
Q3 		$18.7K Buy
4,300
+3,900
+975% +$21.2K 0.01% 817
2024
Q2 		$1.86K Buy
+400
New +$2.15K ﹤0.01% 973

Other funds holding BDTX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Connor, Clark & Lunn Investment Management (CC&L)
Connor, Clark & Lunn Investment Management (CC&L) Vancouver, British Columbia, Canada $52.8B AUM 58.98% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

nVerses Capital's BDTX Position: Q2 2026 in Review

nVerses Capital sold out of Black Diamond Therapeutics (BDTX) in Q2 2026, closing a stake of 31,411 shares — an estimated $66.9K sold.

nVerses Capital first reported a position in BDTX in Q2 2024 and held it in 4 quarters. The position peaked at $66.9K in Q1 2026. 64 funds tracked by Wall St. Rank hold BDTX as of Q2 2026.

  • nVerses Capital reported no remaining Black Diamond Therapeutics position as of Q2 2026 after selling out during the quarter.
  • nVerses Capital sold 31,411 Black Diamond Therapeutics shares in Q2 2026, an estimated $66.9K.
  • nVerses Capital first reported a position in Black Diamond Therapeutics in Q2 2024 and held it in 4 quarters.
  • nVerses Capital's Black Diamond Therapeutics position peaked at $66.9K in Q1 2026.
  • 64 funds tracked by Wall St. Rank held Black Diamond Therapeutics as of Q2 2026.

Based on nVerses Capital's 13F filing for Q2 2026, filed 4 Aug 2026.